Last checked at 22 Dec 2020 07:00
22 December 2020
Nuformix plc
(the "Company" or the "Group")
Appointment of Broker
Nuformix plc (LSE:NFX), a drug re-purposing specialist, is pleased to announce the appointment of Allenby Capital Limited as the Company's sole Broker with effect from today.
Allenby Capital currently advise over 60 corporate clients listed on the London Stock Exchange main market, AIM or Aquis exchanges. Allenby Capital will provide access for Nuformix to a broad spectrum of investors including institutional investors, family offices, private client brokers and high net worth individuals.
Enquiries:
Nuformix plc | +44 (0)1223 627222 |
Dr Anne Brindley, CEO |
|
Fleur Wood, Investor Relations Email: fleur.wood@nuformix.com
|
|
|
|
Allenby Capital Limited | +44 (0)20 3328 5656 |
Tim Sohal / Matt Butlin (Sales and Corporate Broking) Nick Athanas (Corporate Finance)
|
|
About Nuformix plc:
Nuformix is a pharmaceutical development company focused on unlocking the therapeutic potential and value of known drugs to develop new novel medicines which provide therapeutic and commercial advantages to the currently available drug form. Nuformix's model of repurposing drugs utilises many technologies but is focussed on its acknowledged expertise in the use of cocrystal technology through which the Group has developed and patented novel forms of small molecules. Its platform is not therapy-specific but instead has broad application across a wide range of indications. Using its technology, the Group is developing proprietary medicines for its own development pipeline and in partnership with pharmaceutical and biotech companies.
Nuformix plc shares are traded on the London Stock Exchange's Official List under the ticker: NFX. For more information please visit www.nuformix.com .